# Clinical Data on Spinraza for Later-Onset SMA

Keywords: SMA, Spinraza, nusinersen, CHERISH study, motor function, HFMSE, Type II SMA, Type III SMA, clinical trial, adverse events

> This page provides detailed clinical information about the use of Spinraza (nusinersen) in treating later-onset spinal muscular atrophy (SMA), focusing on motor function improvements, safety outcomes, and study results from the CHERISH trial.

## Details

- [Natural history of untreated SMA](#): Individuals with later-onset SMA (Type II and Type III) typically experience a decline of 0.56 points per year in HFMSE scores.
- [Motor function improvements](#): Patients treated with nusinersen in the CHERISH study showed a 3.9-point mean increase in HFMSE scores at 15 months compared to a 1-point decline in sham-control patients.
- [HFMSE](#): The HFMSE is a 33-item scale assessing motor function, with scores ranging from 0 to 66, where higher scores indicate better performance.
- [Study description](#): The CHERISH study was a Phase III randomized, double-blind trial involving 126 children with later-onset SMA, assessing nusinersen's efficacy over 15 months.
- [Adverse event reporting](#): Adverse events can be reported via national health authorities or directly to Biogen through email or phone.